by Asa Elmore | Jul 29, 2021 | Events, News, Presentations, Press Releases
Sutro Biopharma to Participate in the 12th Annual Wedbush PacGrow Healthcare Virtual Conference SOUTH SAN FRANCISCO, Calif., July 29, 2021 – Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the...
by Asa Elmore | Jun 15, 2021 | Events, News, Press Releases
Sutro Biopharma to Participate in Two Virtual Investor Conferences in June SOUTH SAN FRANCISCO, Calif., June 15, 2021 – Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise...
by Asa Elmore | Jun 1, 2021 | News, Press Releases
Sutro Biopharma Earns Milestone Payment from Bispecific Antibody-Drug Conjugate Collaboration with Merck KGaA, Darmstadt, Germany SOUTH SAN FRANCISCO, Calif., June 1, 2021 – Sutro Biopharma, Inc. (NASDAQ: STRO), clinical-stage drug discovery, development and...
by Asa Elmore | May 19, 2021 | Events, News, Presentations, Press Releases
Sutro Biopharma Announces Additional Data for Dose-Escalation Phase 1 Study of STRO-002 to be Presented at ASCO 2021 Maturing data from the Phase 1 dose-escalation cohort for STRO-002 showed a median progression-free survival of 7.2 months One patient achieved a CR...
by Asa Elmore | May 14, 2021 | Events, News, Presentations, Press Releases
Sutro Biopharma to Participate in Upcoming Virtual Investor Conferences SOUTH SAN FRANCISCO, Calif., May 14, 2021 – Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise...
by Asa Elmore | May 7, 2021 | News, Press Releases
Sutro Biopharma Reports First Quarter 2021 Financial Results, Business Highlights and 2021 Anticipated Milestones – Additional follow-up data on STRO-002 from the Phase 1 dose-escalation will be presented at ASCO 2021; enrollment for the dose-expansion is...
